Introduction
Genomic instability occurs in almost all human cancers, but whether it is an active force during cancer evolution or simply a consequence of tumour progression has been a subject of debate [1, 2] . Evidence now suggests that DNA damage occurs early in tumorigenesis in a wide array of cancers [3, 4] . This is before signs of telomere attrition or hypoxia, which have long been known to cause DNA damage [4] [5] [6] [7] [8] . Instead it has been proposed that activated oncogenes, selected for their ability to promote proliferation, cause replicative stress. This replicative stress, characterised by increased numbers of stalled and collapsed replication forks, accounts for early DNA damage [3, 4] . In precancerous lesions, this DNA damage triggers a strong DNA damage response (DDR), which induces senescence or apoptosis, forming a barrier against tumour progression [9, 10] . Only when further genetic or epigenetic changes down-regulate the DDR, usually via the tumour suppressor p53 pathway, is tumorigenesis able to proceed. Patterns of DNA damage and oncogenic mutations in mouse cancer models and human tumours support the oncogene-induced replicative stress model over other models of oncogeneinduced senescence, such as that mediated by the tumour suppressor ARF (reviewed in [11, 12] ). Therefore in the early stages of tumorigenesis, replicative stress appears to be responsible for generating genomic instability and a DDR to limit cancer development, and this in turn provides the selective pressure for acquisition of further mutations that promote tumour progression.
Given its apparent key role in the early stages of cancer development, surprisingly little is known about the nature of oncogene-induced replicative stress. It is possible it is caused by replication of a damaged DNA template, for example caused by reactive oxygen species [13, 14] , but oncogene-induced replicative stress in cultured cells is independent of oxidative stress [3] . Instead recent data suggest that activated oncogenes might have a more direct effect upon the regulation of DNA replication, and this will be the focus of our review. We begin by summarising our current understanding of replication initiation and its regulation, focussing on metazoans, before describing potential mechanisms for oncogene-induced replicative stress and how they trigger DNA damage. Finally we discuss how replicative stress might promote the types of genomic instability commonly seen in cancers and how the causes of replicative stress might change as cancer evolves.
DNA Replication Initiation and Its Regulation
The eukaryotic cell cycle is driven by periodic oscillations in the activity of cyclin-dependent kinase (CDK), due to periodic, antiphase oscillations of cyclin synthesis and the anaphasepromoting complex/cyclosome (APC/C), which targets cyclins for degradation. APC/C activity is high and CDK activity low from late mitosis through G1 phase. G1 cyclins (cyclin D in metazoans), which accumulate in response to mitogenic signalling, trigger the phosphorylation and inactivation of the retinoblastoma protein (RB), a cell cycle inhibitor. This releases the transcriptional activator E2F ( Figure 1A ; reviewed in [15] ), which promotes expression of the G1/S and S phase cyclins (cyclins E and A, which bind to CDK2 in G1/S, in metazoans) along with various other proteins required for S phase progression, including the replication factors Cdc6 and Cdt1, discussed below. High CDK activity drives entry into S phase and inhibits APC/C activity. High CDK activity is maintained through G2 phase and mitosis. Ultimately, mitotic cyclin-CDK (cyclin B/Cdk1 in metazoans) promotes its own inactivation by reactivating the APC/C, which triggers mitotic exit and the start of the low CDK period of the next cell cycle.
Replication must be strictly coordinated with the cell cycle to ensure faithful duplication of the genome. The first step in replication initiation is the assembly of prereplicative complexes (pre-RCs) at replication origins, a process known as licensing. During licensing, the core replicative helicase component, the hexameric minichromosome maintenance 2-7 (MCM) complex, is loaded around double-stranded DNA as an inactive double hexamer ( Figure 1B ) [16] [17] [18] . Loading MCM requires several other pre-RC factors: the six subunit origin recognition complex (ORC; subunits Orc1-6), Cdc6 and Cdt1. At the G1/S transition, two kinases, CDK and Dbf4-dependent kinase (DDK), activate the MCM helicase, which involves the recruitment of Cdc45 and the heterotetrameric GINS complex to form the CMG complex [19] [20] [21] . The conversion of pre-RCs into bidirectional replisomes requires a host of other factors, including Sld2 (RecQL4 in metazoans), Sld3 (Treslin/TICRR in metazoans), Sld7 (currently no clear orthologue identified, but MTBP may perform a similar role in metazoans [22] ), Mcm10 and Dpb11 (TopBP1 in metazoans) ( Figure 1B ).
Preventing Re-Replication
To ensure replication happens once and only once during the cell cycle, the two steps of replication initiation, origin licensing and firing, are temporally separated. This separation is coordinated by changes in CDK activity. High CDK activity triggers origin firing and marks the start of S phase. CDKs also inhibit assembly of pre-RCs so once an origin has fired it cannot be relicensed until the cell has exited the subsequent mitosis, ensuring origins fire just once in each cell cycle. CDK phosphorylates and inhibits various pre-RC components: in the budding yeast Saccharomyces cerevisiae, CDK phosphorylation causes ubiquitin-mediated proteolysis of Cdc6 by CRL1 Cdc4 [23, 24] , nuclear export of the MCM complex [25, 26] and inactivation of Orc2 and Orc6 [27] [28] [29] [30] . In mammalian cells, CDK phosphorylation of pre-RC components can also play a direct role in blocking licensing ( Figure 2 ). Phosphorylated Cdt1 and Orc1 are targeted for ubiquitin-mediated degradation by CRL1 Skp2 [31] [32] [33] and phosphorylation and ubiquitylation of Orc1 can cause its nuclear export during S and G2 phase [34] . Orc2 chromatin binding is inhibited upon CDK phosphorylation [32, 35] . Cdc6 is also phosphorylated by CDK during S phase but how this inhibits pre-RC assembly is still unclear. Ectopic overexpressed Cdc6 is exported from the nucleus during S phase [36, 37] , and consistent with this a pool of endogenous Cdc6 has been shown to be exported [38] . However, the chromatin-bound fraction of endogenous Cdc6 remains unaltered throughout S phase [38] [39] [40] .
There are two further mechanisms to inhibit origin licensing outside of G1 phase in metazoans, and both act on the pre-RC factor Cdt1 (Figure 2 ; reviewed in [41] ). First, geminin, an APC/C target that is present from S through to M phase, binds Cdt1 and inhibits its chromatin binding [42-46]. Second, chromatin-bound Cdt1 is subjected to replication-coupled PCNA-mediated ubiquitination and proteolysis by the CRL4 Cdt2 pathway [47] [48] [49] . Because APC/C activity and the onset of DNA replication are both regulated by CDK, these two mechanisms are indirectly CDK-dependent.
The Licensing Checkpoint
In yeast, if pre-RC assembly is partially inhibited during G1 phase, cells enter S phase with reduced numbers of origins and this causes genomic instability, as discussed below [50] [51] [52] [53] . However, if origin licensing during G1 phase is inhibited in human cells by expression of non-degradable geminin [54] or depletion of pre-RC factors [55] [56] [57] [58] , cells arrest in G1 phase. How pre-RC assembly is monitored by this 'licensing checkpoint' and how this signal is transduced to downstream targets is still unclear. However, it is clear that licensing inhibition results in a reduction in cyclin E/CDK2 activity and concomitant Rb hypophosphorylation [56] [57] [58] , suggesting that the checkpoint works by maintaining repression of E2F to prevent S phase entry. This has been linked to an increase in levels of the CDK inhibitors p27 and p21 [57] , an independent reduction in cyclin D expression [56] and a loss of CDK2-activating phosphorylation and nuclear accumulation [58] . Maintenance of the licensing checkpoint also requires p53, since p53 depletion from licensing-deficient cells overcomes G1 arrest and allows progression into S phase [58] .
Temporal Program of Replication
Origins do not all fire simultaneously at the onset of S phase, but follow a predetermined temporal pattern [59, 60] . In assembly. Cyclin D/CDK4 phosphorylates and inactivates RB, which releases E2F from inhibition. E2F then promotes expression of various genes required for S phase entry. Cyclin E is an E2F target, which completes phosphorylation and inactivation of RB, thereby providing positive feedback to drive cells into S phase. The RB-E2F pathway becomes deregulated by various oncogenes (in green) and tumour suppressor genes (in red), to promote S phase entry and cell proliferation. (B) Replication initiation occurs in two temporally separated steps, origin licensing and origin firing. Origin licensing occurs from late mitosis to the end of G1, when CDK activity is low. ORC, Cdc6 and Cdt1 cooperate to load the MCM2-7 complex onto chromatin as an inactive head-to-head double hexamer around double-stranded DNA. At the G1/S transition, origin firing begins, driven by the action of two kinases, CDK and DDK. The conversion of an inactive double hexamer into two functional replisomes involves several firing factors, including Sld2, Sld3, Sld7, Mcm10, Dpb11 and DNA polymerase ε, which together aid the recruitment of Cdc45 and GINS to form the CMG complex, which stimulates the helicase activity of the MCM2-7 complex. Origins do not fire synchronously during S phase and the time of origin firing is associated with the time of association of firing factors.
budding yeast, limiting levels of firing factors, including Cdc45, Sld3, Sld2, Sld7, Dpb11 and Dbf4 [61, 62] , are recruited preferentially to early-firing origins during G1 and only to late-firing origins during S phase [63, 64] , resulting in temporally ordered origin firing (discussed in [65] ). In human cells, at least Cdc45 also appears to be limiting for replication [66] .
Replicative Stress Following Inappropriate Origin Licensing or Firing Together, the regulatory pathways described ensure that the genome is accurately duplicated in each cell cycle. If any of these pathways are disrupted, origin usage during S phase will be altered. In this section we summarise evidence indicating that replicative stress and genome instability can be caused by reduced origin usage, increased origin usage or re-use of origins in a single cell cycle. We also discuss each of these with respect to oncogenesis.
Origin Under-Usage
Reducing the levels of pre-RC factors or increasing the levels of licensing inhibitors can result in fewer MCM complexes being loaded onto DNA and fewer origins firing in S phase. In budding yeast, which lacks a licensing checkpoint, increasing G1 CDK activity by overexpressing a G1 cyclin or deleting a CDK inhibitor inhibits the assembly of preRCs and causes cells to enter S phase with reduced numbers of active origins [52, 53] . The licensing checkpoint prevents S phase entry in normal mammalian cells with reduced origin licensing. In cancer cells, however, the licensing checkpoint is often compromised, presumably because the p53 and Rb/ E2F pathways that mediate the checkpoint are frequently deregulated, either by mutation or through oncogenic signalling (reviewed in [15] ). Thus, when licensing is inhibited, cancer cells enter S phase with reduced numbers of functional replication origins [54, 55, 58] .
In yeast, inhibition of origin licensing causes genomic instability; entering S phase with too few active origins causes double-strand breaks (DSBs), increased recombination and gross chromosomal rearrangements [50] [51] [52] [53] . In human cancer cells lacking a functional licensing checkpoint, licensing inhibition causes DNA damage, an abortive S phase and apoptosis [54, 55, 58] .
Despite the fact that MCMs are loaded onto DNA in 3-10-fold excess over those used for normal origin firing [67] [68] [69] , reducing licensing still affects genome stability. This is because these excess or 'dormant' origins [70] are required to act as back-ups in times of replication fork stalling and collapse during S phase, since origins cannot be licensed at this stage (reviewed in [71, 72] ). There is evidence that extra origins can be selected for activation in G1 in response to replicative stress in the previous S phase, which may be important in cells experiencing chronic replicative stress [73] . Nonetheless, it is possible to deplete MCMs to such a level that normal replication is not perturbed, and a licensing checkpoint is not activated in normal mammalian cells, but the number of dormant origins is reduced. These cells are hypersensitive to exogenous forms of replicative stress, which increase the frequency of fork stalling, resulting in DNA lesions and checkpoint activation [70, [74] [75] [76] . They also tend to show higher levels of spontaneous DNA damage presumably because there is more fork stalling even in an unchallenged S phase [75] [76] [77] [78] .
Thus, entering S phase with a reduced number of potential origins promotes DNA damage and genome instability in yeast and human cells. The mechanism by which reduced licensing generates damage is unknown. One possibility is that each fork has to cover a greater distance, which might increase the chance of replication fork stalling. Once a fork stalls, there will also be fewer dormant origins available for rescue, and therefore the stalled fork may persist, increasing the likelihood of the fork collapsing and DSBs developing. The reduction in origin usage may also increase the probability that cells will enter mitosis with incompletely replicated DNA. The presence of replication intermediates will prevent efficient chromosome segregation and cause chromosome breakage during mitosis [79] . Mitotic abnormalities, including lagging chromosomes, anaphase bridges and acentric chromosomes as well as micronuclei have been shown to develop in response to licensing inhibition, through CDK misregulation or MCM depletion [52, 76, 80] .
Mouse models of licensing deficiency have been developed where the numbers of licensed origins are reduced but the animals are still viable. Both the Mcm4 chaos mutant and the Mcm2 IRES-CreERT2 mouse are cancer-prone, developing a variety of tumours dependent on genetic background [77, 81, 82] . Tumorigenesis is accelerated in a p53-deficient background suggesting that the DDR acts as an anti-cancer barrier in response to replicative stress [77] . This suggests, at least in mouse models, that licensing inhibition could be a driving force behind tumorigenesis.
In most human cancers, the pathways that control CDK2 activation during G1 become deregulated ( Figure 1A ; reviewed in [83, 84] ). In addition to driving uncontrolled proliferation, this might also limit the low CDK 'window' during G1 phase, resulting in reduced levels of origin licensing, similar to the situation in yeast [52, 53] . Cyclin E, a G1/S cyclin and positive regulator of CDK2, is frequently deregulated in malignancies, associated with gene amplification or more commonly with disruption of the pathways that control its periodicity [85, 86] . Overexpression of cyclin E in human cells causes genomic instability and specifically inhibits MCM chromatin binding during G1, causing a reduction in origin firing during S phase [87, 88] . Longer replication tracks and increased fork stalling are seen upon cyclin E , and phosphorylation and ubiquitylation of Orc1 also causes nuclear export. Additionally, Cdt1 is degraded by the CRL4 Cdt2 pathway via replication-coupled PCNA-mediated ubiquitination and is sequestered by geminin, preventing its chromatin binding.
overexpression, both characteristic of licensing inhibition [3, 89] . Although these experiments were performed on cancer cells, which presumably lack a functional licensing checkpoint, one might predict that overexpression of cyclin E would override the checkpoint and promote S phase entry with insufficiently licensed origins even in cells with an otherwise functional licensing checkpoint. Consistent with this, overexpression of various oncogenes seems to compromise the licensing checkpoint; HPV E7 sensitises cells to MCM depletion [56] , a KRAS mutant sensitises cells to Cdc6 depletion [90] and Myc overexpression sensitises cells to Orc1 depletion [91] . It will be interesting to investigate whether these and other oncogenes also indirectly inhibit licensing, by deregulating CDK activity in order to promote cell cycle entry.
Origin Over-Usage Increasing the number of active origins in S phase or disturbing the temporal program of origin activation can also promote genomic instability. In budding yeast, increasing levels of the normally limiting firing factors causes increased firing of replication origins in early S phase, and this is associated with DNA damage and reduced viability [61, 62, 92] . Similarly, increasing the level of Cdc45 in Xenopus causes increased early origin firing and a DDR [93] . While transient overexpression of Cdc45 in human cells causes increased origin firing, constitutive overexpression results in reduced proliferative capacity, suggesting that increased early origin firing is detrimental for cells [66] .
Experiments aimed to directly manipulate the replication timing program in a variety of organisms suggest that origin over-usage can promote genomic instability. Increased origin activity may exhaust substrates required for replication, such as deoxynucleoside triphosphates (dNTPs; discussed in [94] ) and RPA [95] . This would presumably result in reduced fork speed and an increased chance of fork stalling. Asymmetric forks, which are thought to be an indicator of fork stalling, are seen when origin activity is directly increased in yeast and DNA damage can be rescued by increasing dNTP levels in vivo [61] . RPA is not only limiting for replication but also has a protective role in preventing DNA damage; RPA coats both newly generated singlestranded DNA (ssDNA) at ongoing replication forks and stretches of ssDNA persisting at stalled forks, shielding it from nucleases. Excessive origin firing can deplete RPA and therefore increase DSB formation at unprotected ssDNA [95] .
Increased numbers of replicons may clash with other processes that occur on DNA, such as transcription. Transcription occurs during S phase but, like replication, is temporally and spatially regulated in such a manner that it is generally separated from replication territories [96, 97] . Even so, there are situations, even in an unperturbed S phase, where replication and transcription machineries encounter one another and this causes replication forks to stall until the block is bypassed (reviewed in [98] ). An increase in the number of forks due to origin over-usage or disruption of the temporal regulation of replication may increase the chance of replication-transcription collisions and thus increase the chance of fork collapse and DNA damage.
Overexpression of several oncogenes, including cyclin E, HPV E6 and E7, Myc and Ras, reduces inter-origin distance in human cells, indicating that, at least in localised regions, origin firing is increased [10, 89, 99, 100] . Each of these oncogenes also causes a hyperproliferative phenotype by accelerating the G1/S transition ( Figure 1A) , suggestive of deregulated CDK activation. In fact, in Xenopus egg extracts, simply increasing CDK activity causes late origins to fire early [101] , so this seems a likely explanation for increased origin firing in response to oncogenic activity.
The oncogene Myc may influence origin activation more directly, since it binds DNA close to replication origins, interacts with members of the pre-RC and colocalises with replication foci in early S phase [99] . Myc is known to antagonise the CDK inhibitor p27 [102] and therefore has been suggested to lower the threshold of CDK required locally at replication origins [93] . In Xenopus egg extracts, adding p27 to levels that would normally inhibit replication rescues over-initiation following excess Myc addition, suggesting that p27 counteracts the effects of Myc [93] .
Alternatively, activation of supernumerary replication origins by oncogenes may be a secondary consequence of some other form of replication stress. As discussed above, dormant origins can be activated by factors which slow or stall replication forks, thus reducing inter-origin distance [74, 75] . This might go some way to explaining why cyclin E overexpression appears to have dual effects on replication initiation, both reducing licensing and increasing origin firing, if these effects occur sequentially. Alternatively these conflicting results might be explained by the way in which cyclin E is upregulated in different systems. Cyclin E expression is normally restricted to S phase but if overexpression causes it to become deregulated relative to the cell cycle, this would limit the low CDK period in G1 and inhibit licensing. In contrast, if cyclin E overexpression causes higher levels specifically in S phase, increased origin activity would ensue.
Oncogene-induced replicative stress shows many of the characteristics of stress induced by increased origin firing. For example, replicative stress induced by some oncogenes can be rescued by addition of exogenous nucleosides, suggesting nucleotide levels may have become depleted, perhaps as a consequence of origin over-usage [10, 89, 99, 100] . In addition cyclin E overexpression has been shown to specifically increase the extent of replication-transcription interference, and cyclin E-induced replicative stress can be limited using transcription inhibitors [100] .
Origin Re-Usage If inappropriate re-licensing of replication origins occurs from S to mitosis, when CDK levels are high, origins may fire more than once within a single cell cycle and this can result in re-replication of DNA.
In eukaryotes, there are several overlapping mechanisms acting to prevent re-licensing, as already discussed. The redundancy in the system suggests that disrupting one such pathway should not result in re-replication. This is certainly true in budding yeast; only when all three CDK regulatory pathways are inhibited, by expression of pre-RC mutants refractory to CDK regulation, is significant re-replication observed [27] . Similarly, in mammalian cells, overexpression of the CDK targets Cdc6 or ORC does not cause substantial re-replication [34, 36, 103, 104] . The third target of regulation in metazoans, Cdt1, is more tightly regulated, being inhibited by CDK, geminin and CRL4-dependent degradation, suggesting its deregulation might be more harmful to the cell [41]. Consistent with this, in Xenopus egg extracts, Drosophila and mammalian cells, excess Cdt1 alone can induce re-replication, indicating that the Cdc6 and ORC regulatory pathways are not sufficient to block re-replication when Cdt1 is overexpressed [43, 46, [104] [105] [106] [107] [108] [109] [110] [111] [112] . Interestingly, this response to Cdt1 overexpression is seen in cancer cells but not in normal primary or immortalised human cells [103, 104, 107] . In fact in normal mammalian cells, like yeast, it seems that extensive re-replication only occurs when all three inhibitory targets of the pre-RC are overexpressed [113] . The propensity of cancer cells to re-replicate upon deregulation of Cdt1 suggests that some of the normal, redundant regulation of licensing has been compromised. This may be due, in part, to the fact that many pre-RC factors are already overexpressed in cancer (reviewed in [114] and discussed below).
Re-replication can cause cell death and genome instability [28, 46, 115] . In yeast, Xenopus egg extracts and human cells, re-replication causes checkpoint activation associated with the appearance of ssDNA and DSBs [43, 46, 104, 106, 107, [116] [117] [118] [119] [120] . In addition, there is evidence to suggest that normal but not cancer cells possess a separate checkpoint that limits re-replication in its very early stages [104, 107] . This ATR-mediated checkpoint may detect ssDNA that accumulates early on during re-replication due to extensive DNA unwinding by the replicative helicase at re-licensed origins, uncoupled from DNA synthesis, perhaps due to an imbalance in levels of polymerases and replication origins [107] .
Precisely how re-replication causes DNA damage and activates checkpoints is still unclear, but several mechanisms have been proposed. If re-initiation of replication is infrequent, the resulting replication forks will be relatively isolated and therefore will have to travel some distance before meeting another fork, which increases the chance of fork stalling (discussed in [121] ). Since the fork is unlikely to be rescued by a neighbouring fork, the stalled fork will persist, increasing the likelihood of fork collapse and DNA breakage. If re-initiation from any origin is a frequent event, there is the chance that replication forks will end up 'chasing' one another along DNA, potentially causing head-to-tail collisions and irreversible fork stalling, as has been seen in Xenopus egg extracts supplemented with excess Cdt1 [117] . Deregulated origin firing can also rapidly generate ssDNA gaps due to fork collapse, which act as obstacles for re-replicating forks and induce further fork stalling, collapse and DSBs [122] .
Origin re-firing may increase the number of replication forks during S phase, in a similar manner to origin overusage. In turn it might also cause replication elongation factors to become depleted or clashes with transcription. Alternatively, origin re-firing and the associated replicative stress may inhibit origin firing via activation of DNA damage checkpoints [72] , which might lead to an overall reduction in origin firing, and the potential problems associated with this (see above).
It has been proposed that re-replication has some role to play during cancer progression. Licensing factors are frequently upregulated in cancer cells [100, 103, 119, [123] [124] [125] . This is not simply due to increased cell proliferation since it does not correlate with other proliferation markers, such as Ki-67, suggesting the increased levels may cause misregulation of the replication licensing system. The pre-RC factors Cdt1 and Cdc6 can both act as oncogenes; transgenic Cdt1 mice and mice injected with Cdt1-or Cdc6-overexpressing cells develop tumours [119, 126, 127] . Many pre-RC factor encoding genes are E2F targets [128] and, since the Rb/E2F pathway is frequently deregulated through oncogenic signalling, this might explain why overexpression of licensing proteins is so common. In fact, Cdc6 has been shown to be directly upregulated in response to Ras, cyclin E and Mos overexpression [3, 10, 129] . Moreover, cyclin E and Ras can cause re-replication in human cells when over-expressed [3, 10] .
Replicative Stress Promotes Genomic Instability Several mechanisms have been proposed to explain how replicative stress leads to genome instability. Common fragile sites (CFSs) are segments of the genome prone to breakage when cells are exposed to replicative stress, and are already expressed (i.e. broken) in precancerous lesions when the DDR is still active, suggesting DNA damage at these sites is one of the earliest steps in tumorigenesis [3, 4] . These sites tend to occur in late-replicating, AT-rich regions and are often associated with large genes. Accordingly, some CFSs are particularly susceptible to replication-transcription interference, since replication and transcription often occur simultaneously on long open reading frames [130] . Activated oncogenes that increase the frequency of origin firing or alter the replication timing program could thereby increase the chance of collisions and therefore the chance of fork stalling and collapse.
In contrast, for many CFSs the instability of the site does not correlate with its expression level [131] . Instead, it appears these sites are intrinsically difficult to replicate. Many CFSs are prone to breakage under reduced licensing conditions, for example after MCM depletion [132] . This is because CFSs appear to be either origin-deficient [133] or activate all dormant origins under unchallenged conditions due to AT-rich sequences that promote fork stalling [132] .
Recently other genomic regions have been found to be particularly sensitive to replicative stress; these have been termed early-replicating fragile sites (ERFSs) and are located in highly transcribed, repetitive and CpG-rich regions. Here, replication-transcription collisions certainly appear to play a role in instability. Similarly to CFSs, these sites have also been shown to be sensitive to oncogene activation [134] .
As well as preferentially targeting CFSs and ERFSs, all types of replicative stress discussed in this review can induce genome-wide fork stalling. This can result in immediate fork collapse and breakage during S phase but many replication intermediates, particularly at CFSs, persist into mitosis [135, 136] , presumably because they replicate late and remain shielded by RPA [95] . Frequently the sister chromatids remain interlinked due to under-replication or unresolved replication structures [135] and these are resolved in mitosis by structure-specific nucleases that cleave the DNA to prevent formation of anaphase bridges, generating DSBs [137, 138] . In addition, condensation of chromosomes harbouring unresolved intermediates may also be particularly prone to breakage [136] .
The DSBs generated as a result of replicative stress are precursors for genomic instability; in fission yeast, expression of an inducible replication fork barrier resulted in fork stalling and site-specific gross chromosomal rearrangements [139] . In sporadic cancers, chromosomal instability (CIN) is the most common form of instability, characterised by changes in chromosomal structure and number (reviewed in [12] ). These structural changes, including translocations, amplifications and deletions, can be explained by errorprone repair of DSBs. Non-homologous end joining and microhomology-mediated end joining generate structural rearrangements and loss of material, as well as commonly observed microhomology at breakpoints. Replicative repair pathways, known to occur in yeast, have been proposed to explain the complex structural rearrangements and genomic duplications prevalent in cancer [140, 141] . This involves a stalled replication fork continuing replication on a new template mediated by microhomology. The low processivity of the polymerase causes frequent fork stalling and potentially many rounds of template switching. Recently, breakinduced replication has been shown to occur in human cells and to be responsible for a significant proportion of genomic amplifications in cyclin E-overexpressing cell lines [142] . Although the choice of error-prone pathways might seem surprising, it is possible the homologous recombination machinery becomes overwhelmed by large numbers of DSBs, as is likely the case under conditions of replicative stress (reviewed in [143] ).
Independent of its cause, since all types of replicative stress generate stalled forks and DSBs, the types of CIN generated will be very similar. Origin deficiency is likely to increase the occurrence of under-replicated DNA and therefore may promote genomic loss. Re-replication specifically promotes amplification, because when two forks collapse within a re-replication bubble, the structure generated promotes non-allelic homologous recombination [121] . It seems that certain regions of the genome show a higher frequency of amplification in cancer [144] and there is evidence that chromatin architecture might affect the likelihood of re-replication and copy number gain [145] .
High throughput sequencing has recently revealed the extent of CIN, highlighting extensive intrachromosomal rearrangements and small copy number changes restricted to subchromosomal regions, termed chromothripsis [146] . Replicative stress, through its preferential targeting of CFSs, might start to explain this clustering [143] . Breakinduced replicative repair can also help explain the complex structural rearrangements that are seen. In addition it is known that micronuclei, initially generated by an aberrant mitosis, are particularly prone to replicative stress because they have poor nuclear import of replication and repair factors. When these under-replicated chromosomes undergo 
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Orc2 compaction in mitosis, they can incur multiple DSBs and yet still have the potential to be incorporated into the genome, resulting in clustering of breakpoints [147] . The structural rearrangements caused by replicative stress can go onto cause problems in mitosis, when structurally abnormal chromosomes (usually acentric or dicentric) become misegregated [79] . In this manner structural chromosomal instability can promote numerical chromosomal instability. In addition, further complex chromosomal rearrangements can be generated by subsequent breakage-fusion-bridge cycles [148] .
Although oncogene-induced replicative stress is clearly important for generating genomic instability early on in tumorigenesis, other factors such as telomere attrition and hypoxia are also likely to play significant roles, particularly at later stages.
Replicative Stress during Cancer Evolution
Even single oncogenes can induce replicative stress by different mechanisms depending on context. For example, cyclin E overexpression has been shown to inhibit licensing, increase origin activation and induce re-replication in different experiments [3, 88, 89, 100] and Ras promotes both origin over-usage and re-usage [10] . Thus, it is unlikely that a single type of replicative stress defines any cancer; in fact, evidence suggests that the causes of replicative stress might be quite dynamic during tumorigenesis.
Different mechanisms of replicative stress may also be more or less important at different stages of tumour evolution. A vigorous DNA damage response, presumably activated by replicative stress, can already be seen at one of the earliest detectable stages of cancer, hyperplasia [3, 4] . Levels of pre-RC factors Cdc6 and Cdt1 at this stage, however, are relatively low [119] , suggesting that this replicative stress is unlikely to be due to re-replication. It may be that, in these earliest stages, replicative stress arises from reduced origin licensing. Indeed, acute expression of cyclin E has been shown to reduce licensing and subsequently reduce DNA synthesis within several hours [88] , while experiments which have shown increased origin firing and rereplication have generally examined cells after several days of cyclin E overexpression [3, 80, 89, 100] . Re-replication, and perhaps increased origin firing, probably arises slightly later during tumour development. This hyperactivity of origins requires increased transcription of pre-RC factors through oncogene-induced upregulation of the Rb/E2F pathway and, in human tumour samples, the pre-RC factors Cdc6 and Cdt1 only become upregulated from the stage of dysplasia, well after the DDR is first detected. Moreover, levels of both Cdc6 and Cdt1 increased further on progression from dysplasia to carcinoma, which did not correlate with a simple increase in proliferation rate [119] . In addition, the transformation capability of Cdc6 and Cdt1 overexpression is greater if non-primary cells are used, which are more reflective of the dysplastic stage [119] . Although replicative stress is a hallmark of early tumour progression, and this can be mimicked by manipulating levels of replication factors, mutations in replication factors are rare in cancer ( Figure 3A ). This is not surprising when one considers that replicative stress is actually detrimental to the cell, initially inducing apoptosis or senescence. Also, although replicative stress specifically drives genomic instability, which is important for tumour progression, there is evidence to suggest that primary cells already have high enough mutation rates to account for the number of mutations required to transform cells [2] . Therefore, it seems unlikely that mutations that drive replicative stress would ever be selected alone. Instead oncogenes, selected for their ability to promote proliferation, generate replicative stress as a by-product, due to upregulation of the Rb/E2F pathway and increased CDK activity, and this in turn promotes genomic instability. However, replication factors occasionally become amplified, and this is generally as part of an oncogene cluster, for example Cdc6 is frequently amplified with ERBB2 [119] , and RecQL4 and MTBP are frequently co-amplified with Myc ( Figure 3B ). It is interesting to consider the possibility that amplification of some limiting replication factors along with known oncogenes may increase the fitness of these transformed cells and thus contribute to oncogenesis.
As mutations in p53 and other DDR factors are selected in response to oncogene-induced replicative stress, extensive genomic instability develops. The acquisition of further mutations in oncogenes and tumour suppressor genes may reduce the tumour's dependency on replicative stress as a driving factor for tumour progression. Even so, replicative stress will continue to generate DNA damage and provide the substrates for selection of novel mutations contributing to rapid evolution and genetic heterogeneity in tumours.
Concluding Remarks and Future Perspectives
Evidence suggests that oncogenes deregulate replication initiation and in turn drive genomic instability via various mechanisms (Figure 4 ). Although it now seems likely that oncogene-induced replicative stress has a role to play in early progression of many tumours, further work is required to understand exactly which types of replicative stress contribute towards DNA damage seen in precancerous lesions. The presence of replicative stress in cancer cells has interesting implications for cancer therapies. It may explain why certain tumour types stop responding to traditional genotoxic therapeutics, since replicative stress selects for mutations that overcome the DDR. In addition, it may open up new possibilities for therapeutic targets; for example, in advanced tumours where the DDR has been bypassed, the remaining active components of the DDR pathway may aid the tumour in coping with continuing replicative stress by promoting fork stability and repair. Here, targeting other genes that constitute the DDR pathway may actually suppress tumorigenesis [149, 150] . 
